 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Assistant Professor, School of Pharmacy and Health Professionals, Creighton University, Omaha, NE
Captain, USAF, BSC, Chief, Inpatient Pharmacy Services, Offutt Air Force Base, NE
Reprints: Dr. Boyd, Department of Pharmacy Practice, School of Pharmacy and Health Professions, Creighton University, 2500 California Plaza, Omaha, NE 68178-0401, fax 402/280-1268, sboyd{at}creighton.edu
OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety of rimonabant, a new selective cannabinoid receptor antagonist.
DATA SOURCES: Primary literature and review articles were obtained via a MEDLINE search (1966–November 2004) using the key terms obesity, smoking cessation, cannabinoid, rimonabant, SR 141716, and SR 141716a. Additional studies and abstracts were identified from the bibliographies of reviewed literature.
STUDY SELECTION AND DATA EXTRACTION: Studies and review articles related to rimonabant and the endocannabinoid system were reviewed. Data pertinent to this article were included.
DATA SYNTHESIS: Rimonabant is a selective cannabinoid receptor antagonist. Recent data have demonstrated beneficial effects of rimonabant in obesity, smoking cessation, and metabolic syndrome. Animal studies using rimonabant have shown a positive role for reducing hunger, caloric intake, and body weight and in increasing satiety. In humans, rimonabant appears to be effective for treatment of obesity and smoking cessation. Ongoing studies will examine the effect of rimonabant on obesity, metabolic syndrome, smoking cessation, and alcohol abuse. To date, the incidence of adverse effects with rimonabant has been slightly greater than placebo, with the most common being nausea.
CONCLUSIONS: Rimonabant appears to be a promising drug in an entirely new class called selective cannabinoid CB1 receptor antagonists. The drug may be approved for treatment of obesity and smoking cessation in 2005. Additional studies are ongoing that may provide information on other clinical uses for this medication.
Key Words: endocannabinoid, obesity, rimonabant, smoking cessation
Published Online, March 8, 2005. www.theannals.com, DOI 10.1345/aph.1E499
This article has been cited by other articles:
|
|
 |
|
  C. S. Elangbam Review Paper: Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns Veterinary Pathology, January 1, 2009; 46(1): 10 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Eisenberg MD MPH, K. B. Filion MSc, D. Yavin BSc, P. Belisle MSc, S. Mottillo BSc, L. Joseph PhD, A. Gervais MD, J. O'Loughlin PhD, G. Paradis MD MSc, S. Rinfret MD MSc, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials Can. Med. Assoc. J., July 15, 2008; 179(2): 135 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Addy, P. Rothenberg, S. Li, A. Majumdar, N. Agrawal, H. Li, L. Zhong, J. Yuan, A. Maes, S. Dunbar, et al. Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, in Healthy Male Volunteers J. Clin. Pharmacol., June 1, 2008; 48(6): 734 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Addy, S. Li, N. Agrawal, J. Stone, A. Majumdar, L. Zhong, H. Li, J. Yuan, A. Maes, P. Rothenberg, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, for the Treatment of Obesity: Results From a Double-Blind, Placebo-Controlled, Single Oral Dose Study in Healthy Volunteers J. Clin. Pharmacol., April 1, 2008; 48(4): 418 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ferns and V. Keti HDL-cholesterol modulation and its impact on the management of cardiovascular risk Ann Clin Biochem, March 1, 2008; 45(2): 122 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Dunican, A. R. Desilets, and R. J. DeBellis State of the Art Review: Long-term Pharmacotherapy for Overweight and Obesity: A Review of Sibutramine, Orlistat, and Rimonabant American Journal of Lifestyle Medicine, October 1, 2007; 1(5): 367 - 388. [Abstract] [PDF]
|
|
|
|
 |
|
 C. L. Garwood and L. A. Potts Emerging pharmacotherapies for smoking cessation Am. J. Health Syst. Pharm., August 15, 2007; 64(16): 1693 - 1698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Kakafika, D. P. Mikhailidis, A. Karagiannis, and V. G. Athyros The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome J. Clin. Pharmacol., May 1, 2007; 47(5): 642 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Yuan, K. Z. Al-Shali, and R. A. Hegele Hypertriglyceridemia: its etiology, effects and treatment Can. Med. Assoc. J., April 10, 2007; 176(8): 1113 - 1120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Puechal and J.-N. Fiessinger Thromboangiitis obliterans or Buerger's disease: challenges for the rheumatologist Rheumatology, February 1, 2007; 46(2): 192 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Hoffman, M. Oz, R. Yang, A. H. Lichtman, and C. R. Lupica Opposing actions of chronic {Delta}9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation Learn. Mem., January 1, 2007; 14(1-2): 63 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ellis, J. D. Pediani, M. Canals, S. Milasta, and G. Milligan Orexin-1 Receptor-Cannabinoid CB1 Receptor Heterodimerization Results in Both Ligand-dependent and -independent Coordinated Alterations of Receptor Localization and Function J. Biol. Chem., December 15, 2006; 281(50): 38812 - 38824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Felder, A. K. Dickason-Chesterfield, and S. A. Moore Cannabinoids Biology: The Search for New Therapeutic Targets Mol. Interv., June 1, 2006; 6(3): 149 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T Boyd and B. A. Fremming Update on Rimonabant--A Selective Cannabinoid CB1 Antagonist Ann. Pharmacother., May 1, 2006; 40(5): 994 - 994. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Padwal, S. Majumdar, J.-P. Despres, A. Golay, and L. Sjostrom Metabolic risk factors, drugs, and obesity. N. Engl. J. Med., March 2, 2006; 354(9): 974 - 975. [Full Text] [PDF]
|
|
|
|
|
|
K. J. Miller SEROTONIN 5-HT2C RECEPTOR AGONISTS: POTENTIAL FOR THE TREATMENT OF OBESITY Mol. Interv., October 1, 2005; 5(5): 282 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Sherman The Impact of Smoking and Quitting Smoking on Patients With Diabetes Diabetes Spectr, October 1, 2005; 18(4): 202 - 208. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
